MeVis Medical Solutions AG announced earnings results for the third quarter and year to date ended June 30, 2017. Sales generated in the third quarter of 2017 amounted to EUR 4,440,000, up 17% compared to EUR 3,795,000 a year ago. The development support services provided to Hologic accounted for a substantial share of this increase. Earnings before interest an taxes (EBIT) in the third quarter was EUR 1.7 million against EUR 1.1 million a year ago.

Year to date, the company's sales increased to EUR 14,196,000 against EUR 11,752,000 a year ago. The increase in revenues resulted mainly from the sale of extensive usage rights for the company's tool for the development of software prototypes, MeVisLab, for EUR 1,800,000, which is also included in the following in the sales of the Other Diagnostics segment, as well as from the aforementioned development services for Hologic. EBIT (earnings before interest and taxes) was EUR 5,327,000, up a significant 69% on the previous year's figure of EUR 3,143,000 for the reporting period. The financial result improved year on year, from negative EUR 487,000 to negative of EUR 211,000. The earnings of the 51% share in MeVis BreastCare GmbH & Co. KG, which is recognized at equity, was largely responsible for this. After-tax earnings consequently fell by EUR 1,725,000 to EUR 3,967,000, which is equivalent to undiluted earnings per share of EUR 2.18 against EUR 3.13 a year ago.

The company hold on to the forecast for the current fiscal year 2017 and expect a significant increase in sales to between EUR 17.0 million and EUR 17.5 million and an EBIT of between EUR 5.0 million and EUR 5.5 million.